FDA Rejection News: Recent chatter on social media has centered around a significant setback for Corcept Therapeutics after the FDA issued a Complete Response Letter for its drug relacorilant. Many are discussing the agency’s request for additional evidence of effectiveness, which has led to a sharp decline in the stock price. The drop, reported as high as 50% in some posts, has sparked intense reactions among investors.
Investor Concerns: On social media, users are expressing frustration over the uncertainty surrounding the drug’s future and the company’s next steps. Some have labeled the stock as a risky bet for now, citing challenges in resolving the FDA’s concerns. The dramatic market cap loss has kept the conversation heated and emotional.
Note: This discussion summary was generated from an AI condensation of post data.
Corcept Therapeutics Insider Trading Activity
Corcept Therapeutics insiders have traded $CORT stock on the open market 54 times in the past 6 months. Of those trades, 0 have been purchases and 54 have been sales.
Here’s a breakdown of recent trading of $CORT stock by insiders over the last 6 months:
- JOSEPH K BELANOFF (Chief Executive Officer) has made 0 purchases and 14 sales selling 200,615 shares for an estimated $15,184,726.
- WILLIAM GUYER (Chief Development Officer) has made 0 purchases and 13 sales selling 124,400 shares for an estimated $9,553,300.
- SEAN MADUCK (See Remarks) has made 0 purchases and 12 sales selling 119,795 shares for an estimated $8,906,394.
- JOSEPH DOUGLAS LYON (See Remarks) has made 0 purchases and 10 sales selling 29,900 shares for an estimated $2,233,560.
- DANIEL N JR SWISHER has made 0 purchases and 4 sales selling 8,800 shares for an estimated $667,414.
- GARY CHARLES ROBB (Chief Business Officer) sold 2,326 shares for an estimated $165,774
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Corcept Therapeutics Revenue
Corcept Therapeutics had revenues of $207.6M in Q3 2025. This is an increase of 13.75% from the same period in the prior year.
You can track CORT financials on Quiver Quantitative's CORT stock page.
Corcept Therapeutics Hedge Fund Activity
We have seen 211 institutional investors add shares of Corcept Therapeutics stock to their portfolio, and 195 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC added 1,274,215 shares (+546.9%) to their portfolio in Q3 2025, for an estimated $105,900,008
- FMR LLC added 844,990 shares (+62.3%) to their portfolio in Q3 2025, for an estimated $70,227,118
- JPMORGAN CHASE & CO added 587,053 shares (+223.4%) to their portfolio in Q3 2025, for an estimated $48,789,974
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 541,830 shares (-95.7%) from their portfolio in Q3 2025, for an estimated $45,031,491
- BLACKROCK, INC. removed 482,959 shares (-3.9%) from their portfolio in Q3 2025, for an estimated $40,138,722
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 451,623 shares (-99.2%) from their portfolio in Q3 2025, for an estimated $37,534,387
- UBS GROUP AG added 442,898 shares (+413.8%) to their portfolio in Q3 2025, for an estimated $36,809,252
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Corcept Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $CORT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/25/2025
- Canaccord Genuity issued a "Buy" rating on 09/25/2025
- Piper Sandler issued a "Overweight" rating on 08/01/2025
To track analyst ratings and price targets for Corcept Therapeutics, check out Quiver Quantitative's $CORT forecast page.
Corcept Therapeutics Price Targets
Multiple analysts have issued price targets for $CORT recently. We have seen 4 analysts offer price targets for $CORT in the last 6 months, with a median target of $130.5.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $95.0 on 12/16/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $145.0 on 11/25/2025
- Edward Nash from Canaccord Genuity set a target price of $140.0 on 09/25/2025
- David Amsellem from Piper Sandler set a target price of $121.0 on 08/01/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
